Newsquawk Logo

Novo Nordisk (NOVOB DC) to present new CagriSema and zenagamtide data as it advances its cardiometabolic pipeline at the American Diabetes Association’s 2026 Scientific Sessions

ByNewsquawk Staff
Trade the TapeGet this analysis live, the moment it breaksNewsquawk's real-time dashboard delivers market-moving headlines and instant context to your desk before the rest of the market reacts.
Open Dashboard
#NOVO NORDISK A/S#NOVOB.DC#EU SESSION#US SESSION#EUROPEAN EQUITIES
Published: Updated:
Newsquawk Logo

© 2026 Newsquawk. All rights reserved.